Related Experiment Video
Updated: May 30, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Association between osteopontin promoter variants and diastolic dysfunction in hypertensive heart in the Japanese
Hiroyuki Nakayama1, Hiromi Nagai, Kyotaka Matsumoto
1Department of Clinical Pharmacology and Pharmacogenomics, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
Insights
The -156del/G polymorphism in the Osteopontin (OPN) promoter is linked to worse diastolic dysfunction in hypertensive patients. This suggests OPN plays a role in hypertension-related heart problems.
Area of Science:
- Cardiology
- Genetics
- Molecular Biology
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a growing health concern.
- Diastolic dysfunction, often linked to hypertension, is a key factor in HFpEF development.
- Osteopontin (OPN), a protein mediating fibrosis, is implicated in systolic dysfunction but its role in diastolic dysfunction is unclear.
Purpose of the Study:
- To investigate the association between the Osteopontin (-156del/G) promoter polymorphism and diastolic dysfunction in hypertensive individuals.
- To determine if OPN genetic variants influence left ventricular diastolic function in hypertension.
Main Methods:
- Genotyping of hypertensive patients for the Osteopontin (-156del/G) promoter polymorphism using genomic sequencing.
- Assessment of left ventricular diastolic function via echocardiography, measuring the early to atrial filling (E/A) ratio.
- Statistical analysis including multiple linear regression to identify independent factors.
Main Results:
- Patients with the -156G allele of the OPN promoter exhibited a lower E/A ratio, indicating impaired diastolic function, compared to those with the -156del/del genotype.
- This association was particularly significant in hypertensive patients with diabetes mellitus.
- The -156G allele was identified as an independent predictor of reduced E/A ratio.
Conclusions:
- The -156del/G genetic variants in the Osteopontin promoter are associated with decreased left ventricular diastolic function in hypertensive patients.
- These findings suggest a functional role for Osteopontin in the pathogenesis of diastolic dysfunction within hypertensive hearts.
Abstract:
Heart failure with preserved ejection fraction is recently highlighted as a major health problem, and diastolic dysfunction associated with hypertension has a dominant role in the development of heart failure with preserved ejection fraction. Osteopontin (OPN) is a secreted phosphoprotein, which mediates fibrosis. In animal models, OPN is upregulated in response to pressure overload and is thought to be involved in systolic dysfunction. However, the functional role of OPN in diastolic dysfunction is unknown. The guanine base insertion polymorphism at -156 position of the OPN promoter is postulated to upregulate the transcription of OPN in human. To investigate whether -156del/G polymorphism of OPN promoter is associated with diastolic dysfunction in hypertensive hearts, the patients with hypertension have been genotyped for variants of -156del/G polymorphism by genomic sequencing. Diastolic function of the left ventricle was estimated as the ratio of early to atrial filling (E/A ratio), obtained by pulsed-Doppler derived transmitral flow in echocardiographic analysis. The patients with -156G allele displayed lower E/A ratio compared with those with -156del/del genotype, suggesting exacerbated diastolic function. Notably, in case of the population with diabetes mellitus, the patients with -156G allele showed significant association with lower E/A ratio, compared with -156del/-156del patients. Multiple linear regression analysis revealed that prevalence of -156G allele was an independent factor for lowering E/A ratio. The -156del/G genetic variants of OPN promoter were associated with decreased E/A ratio in hypertensive patients. These results suggest that OPN has a functional role in the development of diastolic dysfunction in hypertensive hearts.
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension and Regulation of Blood Pressure
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Coronary Artery Disease II: Pathophysiology
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
